Elevara

Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.

Latest funding

$70M Series A · October 24, 2025

Led by Forbion Capital Partners · Source: FirstWord Pharma

Funding history ↓

Website: elevara.com.

LinkedIn: linkedin.com.

Category: Health and bio.

Sectors: Biotechnology, Clinical Trials, Therapeutics.

Stage: Series A.

Based in: London, United Kingdom.

Founded: 2026.

Last round: Oct 24, 2025 · 384 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Nov 8, 2026.

Signals

Website registeredJul 6, 2010 (16 years old)

Funding rounds

October 24, 2025
Series A · $70M
FForbion Capital Partners (lead), SSofinnova Partners (lead), MMonograph Capital, WWeatherden
Source: FirstWord Pharma
July 6, 2010
Website created

Founders and team

ET
Emma Tinsley founder and CEO

LinkedIn · source: elevara.com
MZ
Mai-Britt Zocca CEO
KW
Kirsty Wydenbach Head of Regulatory
TF
Tim Funnell Chief Operating Officer

Investors

Companies like Elevara

EEngrail Therapeutics$157M Series B+ · Mar 2024
IInnornaSeries B+ · Apr 2022
AAlzheon$100M Series B+ · Apr 2022
SStorm Therapeutics$56M Series B+ · Apr 2026
AAstrocyte Pharmaceuticals$9.5M Series B+ · Sep 2026
AAirNexis Therapeutics$200M Series A · Jan 2026

Other companies backed by Forbion Capital Partners

OOMass Therapeutics$310M Series B+ · Oct 2026
KKynexis$112.57M Series A · Aug 2026
RRQ Bio$115M Series A · Jun 2026
CCellCentric$220M Series B+ · May 2026
TTropic Biosciences$105M Series B+ · Mar 2026
SSidera Bio$109.99M Series A · Nov 2025

Forbion Capital Partners portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/elevara (get a free API key).